The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin: In vitro Bewertung von Voriconazol gegenüber klinischen Isolaten von Hefen, Schimmelpilzen und Dermatophyten im Vergleich mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin
Abstract
Summary. The in vitro activity of voriconazole (UK‐109, 496), a new antifungal triazole derivative, against 650 clinical isolates of yeasts, moulds and dermatophytes was compared with that of itraconazole, ketoconazole, amphotericin B and griseofulvin. The geometric means of the minimum inhibitory concentrations (MICs) of voriconazole were 0.05 μg ml‐1 against yeasts (n= 187), 0.58 μg ml‐1 against moulds (n= 260) and 0.08 μg ml‐1 against dermatophytes (n= 203). The overall activity of voriconazole against yeasts and moulds was good, being similar to that of itraconazole, ketoconazole and amphotericin B. Voriconazole was highly effective against Aspergillus fumigatus (mean MIC 0.23 μg ml‐1) and other Aspergillus species and showed noteworthy activity (mean MICs 0.08‐0.78 μg ml‐1) against emerging and less common clinical isolates of opportunistic moulds, such as Altenaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. and Fusarium spp. On the other hand, voriconazole was less active in vitro than the comparative agents studied against various species of zygomycetes, such as Mucor spp., Rhizopus spp. and Absidia spp. Voriconazole and the other two azoles, itraconazole and ketoconazole, were more active than griseofulvin in vitro against most dermatophytes tested. Zusammenfassung. Die In‐vitro‐Aktivität von Voriconazol (UK‐109,496), einem neuen antimy‐kotischen Triazol‐Derivat, wurde gegen 650 klinische Isolate von Hefen, Schimmelpilzen und Dermatophyten mit Itraconazol, Ketoconazol, Amphotericin B und Griseofulvin verglichen. Die mittieren MHK‐Werte (minimalen Hemmkonzentrationen) betrugen gegenüber Hefen 0.05 μg ml‐1 (n= 187), Schimmelpilzen 0.58 μg ml‐1 (n= 260) und Dermatophyten 0.08 μg ml‐1 (n= 203). Insgesamt war die Aktivität von Voriconazol gegen Hefen und Schimmelpilze gut und vergleichbar mit Itraconazol, Ketoconazol und Amphotericin B. Voriconazol war sehr wirksam gegen Aspergillus fumigatus (mittlere MHK 0.23 μg ml‐1) und andere Aspergillus‐Spezies und zeigte ein bemerkenswerte Aktivität (mittlere MHK 0.08‐0.78 μg ml‐1) gegen aufkommende und bisher weniger häufige klinische Isolate opportunistischer Schimmelpilze wie Alternaria spp., Cladosporium spp., Acremonium spp., Chrysosporium spp. und Fusarium spp., Andererseits war Voriconazol in vitro gegen verschiedene Spezies von Zygomyceten wie Mucor spp., Rhizopus spp. und Absidia spp. weniger wirksam als die untersuchten Vergleichssubstanzen. Voriconazol und die anderen beiden Azole, Itraconazol und Ketoconazol, waren in vitro gegen die meisten geprüften Dermatophyten wirksamer als Griseofulvin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the administration of azoles for treating fungal infections has encountered certain limitations, such as their low water solubility, low bioavailability, and frequent side effects consequent on the requirement of high doses and/or long-term administration.21,42”
Citations
Cites
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Therapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 683
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
Fungal infections in cancer patients: An international autopsy survey
Bodey, G. P., Bueltmann, B., Duguid, W. P., Gibbs, D. L., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., et al. (1992) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01967060 · Cited by 546
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P. G., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90023-x · Cited by 448
Powderly, W. G., Saag, M. S., Cloud, G. A., Robinson, P. A., Meyer, R. D., Jacobson, J. M., Graybill, J. R., Sugar, A. M., McAuliffe, V. J., Follansbee, S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261203 · Cited by 351
Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
Morrison, V. A., Haake, R. J., & Weisdorf, D. J. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90088-4 · Cited by 214
Radford, S. A., Johnson, E. M., & Warnock, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.841 · Cited by 188
In vitro evaluation of voriconazole against some clinically important fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R., & Rinaldi, M. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1832 · Cited by 132
Antifungal Agents in the 1990s
Kauffman, C. A., & Carver, P. L. (1997) · Drugs · doi:10.2165/00003495-199753040-00001 · Cited by 129
Barry, A. L., & Brown, S. D. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1948 · Cited by 123
Disseminated Infection with Fusarium in Recipients of Bone Marrow Transplants
Gamis, A. S., Guðnason, Þ., Giebink, G. S., & Ramsay, N. K. C. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.6.1077 · Cited by 100
The pharmacokinetics of oral itraconazole in AIDS patients
Smith, D., de Velde, V. V., Woestenborghs, R. J. H., & Gazzard, B. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb05478.x · Cited by 77
Fluconazole in the treatment of oropharyngeal candidosis in HIV‐positive patients
Just‐Nübling, G., Gentschew, G., Döhle, M., Böttinger, C., Helm, E.-B., & Stille, W. (1990) · Mycoses · doi:10.1111/myc.1990.33.9-10.435 · Cited by 30
Pharmacology and Pharmacokinetics of Traditional Systemic Antifungal Agents
Barriere, S. L. (1990) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1990.tb02598.x · Cited by 24
The in vitro activity of fluconazole against fungi involved in dermal infections
Wildfeuer, A., & Seidl, H. (1994) · Mycoses · doi:10.1111/j.1439-0507.1994.tb00398.x · Cited by 22
Self-citationWildfeuer, A., Seidl, H. P., Paule, I., & Haberreiter, A. (1997) · PubMed · Cited by 19
Self-citationKintzel, P. E., Rollins, C. J., Yee, W. J., & List, A. F. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900208 · Cited by 18
Kotoğyan, A., Harmanyeri, Y., Güneş, A. T., Erboz, S., Palali, Z., Sabuncu, İ., Kot, S., Baransü, O., Karaman, A., Yazar, Ş., et al. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199612020-00001 · Cited by 9
DICKINSON, R. P., Bell, A., Hitchcock, C. A., Narayanaswami, S., Ray, S. J., Richardson, K., & Troke, P. F. (1996) · ChemInform · doi:10.1002/chin.199652173 · Cited by 1
Cited by
Sorted by citations
Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F. G. M., Cornely, O. A., & Lortholary, O. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12360 · Cited by 533
Dignani, M. C., & Anaissie, E. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00845.x · Cited by 351
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 312
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Espinel‐Ingroff, A., Boyle, K., & Sheehan, D. J. (2001) · Mycopathologia · doi:10.1023/a:1010954803886 · Cited by 251
Metadata
- Authors
- Wildfeuer, A., Seidl, H. P., Paule, I., & Haberreiter, A.
- Affiliations
- Pfizer (United States) (US)
- Technical University of Munich (DE)
- Corresponding author
- Wildfeuer, A.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 1998-09
- Volume
- 41
- Issue
- 7-8
- Pages
- 309-319
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1992535097
- Cited by
- 140
- References
- 20
- Citations by year
- 2024: 5 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 5 · 2013: 3 · 2012: 2
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Mycoses (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- voriconazole, antifungal activity, yeast, molds, dermatophytes, itraconazole, ketoconazole, amphotericin B, griseofulvin, minimum inhibitory concentration, Aspergillus fumigatus, Zygomycetes, triazole antifungals, clinical isolates
- MeSH terms
- Amphotericin B, Antifungal Agents, Fungi, Griseofulvin, Humans, Ketoconazole, Microbial Sensitivity Tests, Mycoses, Pyrimidines, Triazoles, Itraconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
